EP1829545A1 — Prostaglandin f2 alpha derivative containing products
Assigned to Santen Pharmaceutical Co Ltd · Expires 2007-09-05 · 19y expired
What this patent protects
The present invention provides a resin container in which an aqueous liquid preparation containing a prostaglandin F2± derivative having at least a fluorine atom in its molecule can be stored stably for a long period of time. By storing the aqueous liquid preparation containing t…
USPTO Abstract
The present invention provides a resin container in which an aqueous liquid preparation containing a prostaglandin F2± derivative having at least a fluorine atom in its molecule can be stored stably for a long period of time. By storing the aqueous liquid preparation containing the prostaglandin F2± derivative having at least a fluorine atom in its molecule in the resin container made of a propylene/ ethylene copolymer in which the ratio of a propylene component to an ethylene component is in the range of from 94.0/6.0 to 99.5/0.5 (propylene component/ethylene component), a decrease in the content of the prostaglandin F2± derivative in the aqueous liquid preparation is inhibited.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.